Biophytis will attend the annual JP Morgan Healthcare conference, of January 7th to 10th in San Francisco
Biophytis strengthens its senior management team and continues its expansion in the United States. Read the Press Release
Biophytis Announces One Oral Presentation and Two Poster Presentations at the 11th International Conference on Cachexia, Sarcopenia and Muscle Wasting. Read the Press Release
Biophytis to Host Key Opinion Leader Meeting on the Biology of Aging and its Application in Neuromuscular Diseases. Read the Press Release
Interim results 2018 and perspective on activity. Read the Press Release
Interview with Stanislas Veillet, CEO of Biophytis, at the European Large & Midcap Event, Paris. Watch the video
Interview with Stanislas Veillet, CEO of Biophytis in Le Revenu TV
Biophytis obtains a €10 million loan with Kreos Capital. Read the Press Release
Biophytis Provides Enrollment Update in Its Phase 2b SARA-OBS and SARA-INT Studies of Sarconeos in Sarcopenia. Read the Press Release
BIOPHYTIS to Present at the H.C. Wainwright 20th Annual Global Investment Conference. Read the Press Release
BIOPHYTIS: 2017 Annual Report filed. Read the Press Release
Biophytis appoints a new Chief Medical Officer based in the USA. Read the Press Release
Results of the Extraordinary General Meeting held on June 4, 2018. Passing of all the resolutions. Read the Press Release
Biophytis receives favourable opinion from EMA for the Orphan Drug designation of Sarconeos in Duchenne Muscular Dystrophy (DMD). Read the Press Release
Inclusion of the first patient in Phase 2b Study in Sarcopenia. Read the Press Release
Results of the 2018 Annual Meeting of Shareholders. Read the Press Release
Biophytis receives Orphan Drug Designation from the FDA for Sarconeos in Duchenne Muscular Dystrophy (DMD). Read the Press Release
2017 Annual Financial Report made available. Read the Press Release
BIOPHYTIS updates on clinical development of Macuneos and presents its effects on visual function in a preclinical model of AMD at 2018 ARVO Congress. Read the Press Release
Interview of Stanislas Veillet, CEO of Biophytis for the European Smallcap event 2018 with Didier Testot, journalist on the Web tv www.labourseetlavie.com
BIOPHYTIS : 2017 Full Year Results. Read the Press Release
Biophytis files for Orphan Drug Designation for Sarconeos in Duchenne Muscular Dystrophy (DMD). Read the Press Release
Biophytis updates on SARA clinical study of Sarconeos in sarcopenia and presents four posters at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Miami. Read the Press Release
Biophytis to participate in upcoming sectorial events over the first half of 2018. Read the Press Release
Biophytis to Participate in Corporate Access Event in San Francisco, January 8 – 10, 2018. Read the Press Release
Biophytis Presents 4 Posters on Sarconeos at 10th International Conference on Cachexia, Sarcopenia, and Wasting Disorders (SCWD). Read the Press Release
Biophytis has FAMHP Approval to conduct SARA-INT phase 2b Interventional Study of Sarconeos in Sarcopenia in Belgium. Read the Press Release
Biophytis completes a € 7,5 M capital increase to help accelerate pipeline programs in orphan pediatric diseases. Read the press release
Biophytis has FDA Approval to initiate SARA-INT phase 2b Interventional Study of Sarconeos in Sarcopenia. Read the Press Release
Biophytis appoints Professor Thomas Voit to Scientific Advisory Board to help accelerate pipeline programs in orphan pediatric diseases. Read the Press Release
Half-Year Financial Report as of June 30, 2017. Read the press release
Biophytis will present at the Galien MedStartUp Partnering Day on October 26, 2017 in New York
Biophytis completes a €10.4 M capital increase to finance mid-stage clinical trials for two novel anti-aging drug-candidates. Read the Press Release
Interview of Stanislas Veillet, CEO of Biophytis for the European Large & Midcap event 2017 with Didier Testot, journalist on the Web tv www.labourseetlavie.com
Biophytis filed IND application for approval by FDA of SARA-INT Phase 2b study of Sarconeos in Sarcopenia. Read the Press Release
Biophytis to participate in upcoming industry and investors conferences. Read the Press Release
Biophytis presents the mechanism of action of Macuneos for the treatment of AMD, at the Euretina Congress. Read the Press Release
Biophytis clinical stage drug-candidate Sarconeos demonstrates efficacy in preclinical models of Duchenne muscular dystrophy . Read the Press Release
The report of the Key Opinion Leader Breakfast of july 28, in NYC with Roger Fielding, PhD (Tufts University) made available
Biophytis announces the appointment of Dr Manfred Horst as Business Development Office. Read the Press Release
2016 Reference Document made available. Read the Press Release
BIOPHYTIS selects Appletree CI Group to conduct MACA-OBS, and releases the MACA clinical program schedule of Macuneos in dry AMD. Read the Press Release
Biophytis to Host Key Opinion Leader Breakfast on Sarcopenia in New York – July 28, 8:00 am
Biophytis announces the issuance of a €3 million tranche of ORNANEBSA. Read the Press Release
Video interview of Stanislas Veillet, CEO of Biophytis : “The schedule announced last year is followed”. Click here to watch the vidéo.
Participation of Biophytis to the European MIDCAP event in Hotel Pullman Paris Eiffel Tour – June 28 & 29, 2017
Results of the General Shareholders’ Meeting held on June 16, 2017. Read the Press release
BIOPHYTIS selects SGS Life Science Services to conduct MACA-PK, clinical study of Macuneos in dry AMD. Read the Press Release
Participation of Biophytis to Bio€quity Europe 2017. May 22-23, 2017. Marriott Rive Gauche, Paris, France
Biophytis announces the issuance of a €3 million tranche of ORNANEBSA. Read the Press Release
First patient-in in the United States and opening of 2 clinical centers for the SARA-OBS study on Sarcopenia. Read the Press Release
The SARA clinical program – Towards a first treatment for Sarcopenia. Interviews conducted during ICSFR 2017. Watch the video
BIOPHYTIS confirms that Sarconeos modulates the Renin-Angiotensin System and activates muscular metabolism in the SARA-PK clinical trial. Read the Press Release
Results 2016 Read the Press Release
Biophytis secures funding for phase 2B clinical trial in Sarcopenia, SARA-INT. Read the Press Release
Biophytis opens the first clinical centers in Europe and starts the recruitment of sarcopenic patients for SARA-OBS study. Read the Press Release
Biophytis to present four scientific studies at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Barcelona. Read the Press Release
Full results of SARA-PK study confirm Sarconeos’ good pharmacokinetic profile in elderly patients. Read the Press Release
Biophytis relocates to Pierre and Marie Curie University (UPMC) campus and solidifies creation of leading translational platform for age-related disease. Read the Press Release
BIOPHYTIS to participate to the JP Morgan Annual Healthcare Conference in San Francisco, January 9-12th 2017. Read the Press Release.
Biophytis presents preliminary clinical data of SARA-PK, and new preclinical data of Sarconeos for treating sarcopenia. Read the Press Release
BIOPHYTIS Announces Successful Completion of SARA-PK Clinical Study for Sarconeos in Sarcopenia Confirming Safety Profile. Read the Press Release
Conférence Biotech Agora – December 13, 2016
18h45 – Hôtel ATALA, 10 Rue de Chateaubriand, 75008
BIOPHYTIS received regulatory authorizations to conduct SARA-OBS study in sarcopenia patients. Read the Press Release
Biophytis Presenting Four Posters on Sarconeos at 9th International Conference on Cachexia, Sarcopenia, and Muscle Wasting. Read the Press Release
BIOPHYTIS to attend to Jefferies conference (London) and European Midcap event (Geneva). Read the Press Release
BIOPHYTIS chooses Patheon to produce the clinical batches of Macuneos, its AMD drug candidate that will enter Phase 2B. Read the Press Release
BIOPHYTIS to implement company’s SARA-data e-Health platform for clinical development of Sarconeos in sarcopenia patients. Read the Press Release
Biophytis to attend the European Large & Midcap Event in Paris – 5-6 October, 2016
Video interview of Stanislas Veillet, CEO of Biophytis. Click here to see it
Business Update and Consolidated Half-Year Financials as of June 30, 2016. Read the Press Release
BIOPHYTIS launches the second phase of Sarconeos pharmacokinetics study (SARA-PK) after successful completion of the initial phase. Read the Press Release
BIOPHYTIS ready to launch SARA-OBS trial. Read the Press Release
Biophytis will be present at BIOPHARM AMERICA 2016 in Boston, from September 13 to 15
BIOPHYTIS will present at the Rodman & Renshaw 18th Annual Global Investment Conference In New York City, September 11-13, 2016. Read the Press Release
Enrollment of the first subjects in the pharmacokinetics study on Sarcopenia. Read the Press Release
BIOPHYTIS receives approval of bpifrance for an innovation loan of €1.1M to finance the SARA-PK trial. Read the press release
BIOPHYTIS receives Belgian regulatory authorization to start Sarconeos pharmacokinetics study in elderly healthy volunteers (SARA-PK). Read the Press Release
Results of the Combined General Shareholders’ Meeting held on June 10, 2016. Read the Press Release
BIOPHYTIS to attend BIO International Convention in San Francisco, June 6th to 9th 2016. Read the Press Release and watch the video of Stanislas Veillet
In french: Assemblée Générale convoquée le 10 juin 2016. Téléchargez le communiqué de presse
BIOPHYTIS unveils its clinical development strategy in the United States, as it communicates its 2015 Document de Référence. Download the Press Release
BIOPHYTIS to Present Key Research Findings on Company’s Two Lead Compounds at Upcoming Scientific Conferences. Read the Press Release
BIOPHYTIS: 2015 Annual Results. Read the Press Release
BIOPHYTIS receives positive scientific advice on SARCOB BIO101 clinical development plan from Belgian regulatory authority. Download the Press Release
L’américain LifeSci Capital initie la couverture du titre Biophytis. Téléchargez le communiqué de presse
Biophytis to present at the Biotech Showcase conference run parallel to the JP Morgan Healthcare Conference (San Francisco, January 11-13, 2016). Read the Press Release
Biophytis Appoints of Roger A. Fielding, Ph.D., as a Scientific Consultant for Company’s SARCOB Clinical Development Program. Download the Press Release
Half-year results for 2015. Download the Press Release
Biophytis Appoints Pierre J. Dilda as Director of Research. Read the Press Release
Biophytis to present preclinical proof of concept for Sarcob to treat sarcopenic obesity at SCWD on December 4th. Download the Press Release
Biophytis establishes Boston subsidiary to accelerate clinical development. Download the Press Release
BIOPHYTIS Invited to Attend the Jefferies 2015 Global Healthcare Conference. Read the press release
BIOPHYTIS initiates the clinical batches production of BIO101, the first step in the ongoing phase 2b trial in the sarcopenic obesity. Click here to download the Press Release
BIOPHYTIS completes an international private placement of 6M€ to conduct its development strategy. Click here to download the Press Release
BIOPHYTIS strengthens its senior management team. Click here to download the Press Release
Major mobilisation at the SFO 2015 conference – the 121st Conference of the Société Française d’Ophtalmologie [French Society of Ophthalmology], from 9 to 12 May 2015, at the Palais des Congrès in Paris
Involvement in the 3ème Congrès francophone [3rd French-speaking conference] on assessing fragility in elderly subjects – “Prévention de la Dépendance – Rencontres Scientifiques sur la Sarcopénie” [The Prevention of Dependency – Scientific Fora on Sarcopenia] – Paris, 12 and 13 March 2015.